All In Biotech

Drug Trial Radar · NCT07637851

Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer With Poor Response to First-Line Chemotherapy

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

43

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Sep 2028

Study completion Apr 2030

Sponsor

Lead sponsor
ARCAGY/ GINECO GROUPAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regeneron Pharmaceuticals
First posted
Jun 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer. The main questions it aims to answer are: * What is the safety profile of ubamatamab when administered with carboplatin-paclitaxel ± bevacizumab? * What is the objective response rate after three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab? Participants will: * Receive three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab, followed by maintenance therapy with ubamatamab ± bevacizumab for up to 15 months, depending on HRD status and disease response after the initial treatment cycles. * Attend regular clinic visits throughout the treatment period for checkups and tests

Conditions

  • Ovarian Cancer

Interventions

  • UbamatamabDrug

    Dosage form: Solution for perfusion Dosage: 5 mg/mL; 50 mg/mL Frequency: administration every three weeks Treatment duration: 15 months

  • ChemotherapyDrug

    Carboplatin + Paclitaxel administered at each cycle of 21 days (in total 3 cycles).

  • BevacizumabDrug

    Bevacizumab administered at each cycle of 21 days (3 cycles in total) then during maintenance therapy every 3 weeks.

  • GCSFDrug

    Administered at each cycle during the 3 first cycles of the drug combination (chemotherapy + bevacizumab + ubamatamab).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety run-in phase I : Safety and recommended dose for phase II trial during the Dose-limiting toxicities monitoring periodTime frame: Up to 4 weeks of treatment
  2. Safety run-in phase I : Safety and recommended dose for phase II trial during the Dose-limiting toxicities monitoring periodTime frame: Up to 4 weeks of treatment
  3. Safety run-in phase I : Safety and recommended dose for phase II trial during the Dose-limiting toxicities monitoring periodTime frame: From Cycle 1 Day 1 of the first patient included to Cycle 3 Day 1 of the sixth patient included (each cycle is 21 days) (Safety and Tolerability)
  4. Efficacy phase II partTime frame: 1 month after Cycle 3 Day 1 of the sixth patient included (each cycle is 21 days).

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Institut Bergonié

    Bordeaux, France

  • Centre François Baclesse

    Caen, France

  • Centre Georges François Leclerc

    Dijon, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Paoli Calmettes

    Marseille, France

  • ICM Val d'Aurelle

    Montpellier, France

  • HCL - Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Centre Eugène Marquis

    Rennes, France

  • ICO - Centre René Gauducheau

    Saint-Herblain, France

  • Hôpital de Hautepierre

    Strasbourg, France

  • Gustave Roussy

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.